Evidence map›Paper›PMID 42317403›Full record

ReviewFrontiers in medical technology2026

Gold nanoparticles in skin drug delivery: a bibliometric analysis of research trends from 2015 to 2025.

Mohammed Arif, Karim Mousa, Haider Butt

Abstract readReview
In one paragraph

Review in Frontiers in medical technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mohammed ArifDepartment of Mechanical & Nuclear Engineering, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates.
Karim MousaDepartment of Mechanical & Nuclear Engineering, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates.
Haider ButtDepartment of Mechanical & Nuclear Engineering, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gold nanoparticles (AuNPs) have emerged as highly effective nanocarriers for skin drug delivery due to their tunable physicochemical properties, large surface area, and ease of functionalization. Over the past decade, research in this field has expanded rapidly, driven by advances in nanotechnology and increasing interest in non-invasive topical and transdermal-based therapies. In this study, a comprehensive bibliometric analysis was conducted to evaluate global research trends in gold nanoparticle-based skin drug delivery between January 1, 2015, to December 31, 2025. using the Web of Science and Scopus databases. Publications were identified through structured keyword-based searches focused on "gold nanoparticles" and "skin drug delivery", and analyzed for publication output, leading contributors, research areas, and keyword co-occurrence using VOSviewer. The results reveal a significant growth in publications, particularly after 2020, with major contributions from Asia, especially India and China. Key research themes include wound healing, antibacterial applications, and skin cancer treatment, with an increasing emphasis on nanocarrier design and controlled drug-delivery systems. This study provides a systematic overview of the research landscape, offering insights into emerging trends and influential contributors. However, it is limited by database selection, potential keyword bias, and the descriptive nature of bibliometric analysis, which does not include experimental validation. Despite these limitations, the findings contribute to a clearer understanding of the development and future direction of gold nanoparticle-based skin drug delivery research.

Indexed as

bibliometric analysisgold nanoparticlesnanocarrierskin drug deliverytopical drug delivery

Identifiers

PMID42317403
PMCPMC13272481

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.